Edgestream Partners L.P. Takes $679,000 Position in ICU Medical, Inc. (NASDAQ:ICUI)

Edgestream Partners L.P. acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,374 shares of the medical instruments supplier’s stock, valued at approximately $679,000.

A number of other institutional investors have also modified their holdings of the company. Arizona State Retirement System grew its stake in shares of ICU Medical by 1.0% in the fourth quarter. Arizona State Retirement System now owns 6,730 shares of the medical instruments supplier’s stock valued at $1,044,000 after buying an additional 65 shares in the last quarter. Equitable Trust Co. grew its stake in ICU Medical by 1.6% during the 4th quarter. Equitable Trust Co. now owns 5,297 shares of the medical instruments supplier’s stock worth $822,000 after purchasing an additional 84 shares in the last quarter. Connable Office Inc. grew its stake in ICU Medical by 6.4% during the 3rd quarter. Connable Office Inc. now owns 2,031 shares of the medical instruments supplier’s stock worth $370,000 after purchasing an additional 122 shares in the last quarter. Gagnon Securities LLC grew its stake in ICU Medical by 0.5% during the 4th quarter. Gagnon Securities LLC now owns 28,881 shares of the medical instruments supplier’s stock worth $4,481,000 after purchasing an additional 137 shares in the last quarter. Finally, Wealthspire Advisors LLC grew its stake in ICU Medical by 6.4% during the 4th quarter. Wealthspire Advisors LLC now owns 2,660 shares of the medical instruments supplier’s stock worth $413,000 after purchasing an additional 160 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.70% of the company’s stock.

ICU Medical Trading Up 1.9 %

NASDAQ:ICUI opened at $141.59 on Thursday. The stock has a 50-day simple moving average of $157.96 and a 200-day simple moving average of $165.25. The stock has a market cap of $3.47 billion, a P/E ratio of -30.98 and a beta of 0.73. ICU Medical, Inc. has a 1 year low of $93.36 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. StockNews.com cut ICU Medical from a “buy” rating to a “hold” rating in a research note on Monday. Raymond James set a $97.00 target price on ICU Medical in a research note on Wednesday. KeyCorp boosted their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $168.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.